GMAP-210_TRIP11 Inhibitors
GMAP-210_TRIP11 inhibitors are chemical compounds that target the GMAP-210 (Golgin, Microtubule-Associated Protein 210) protein, also known as TRIP11 (Thyroid Hormone Receptor Interactor 11). GMAP-210/TRIP11 is a large, coiled-coil protein localized in the Golgi apparatus, a central hub for protein sorting, modification, and trafficking within eukaryotic cells. This protein plays a critical role in maintaining the structural integrity of the Golgi apparatus and facilitating the organization and tethering of vesicles that transport proteins and lipids between cellular compartments.
Inhibitors of GMAP-210_TRIP11 are designed to interact with this protein and potentially disrupt its functions, including its role in Golgi tethering and vesicle transport. These inhibitors may operate through various mechanisms, such as binding to specific regions or domains of GMAP-210_TRIP11 or altering its conformation. By inhibiting GMAP-210_TRIP11, these compounds can potentially interfere with the proper organization of the Golgi apparatus, leading to disruptions in intracellular trafficking processes and impairments in the secretion of proteins and lipids. Research on GMAP-210_TRIP11 inhibitors is primarily focused on understanding the molecular mechanisms by which this protein contributes to Golgi structure and function, offering insights into the regulation of vesicle trafficking, cargo delivery, and membrane dynamics within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylases, which could result in chromatin remodeling and potentially decrease GMAP-210 gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound is a DNA methyltransferase inhibitor that can lead to hypomethylation of DNA and potentially downregulate GMAP-210 expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Similar to 5-Azacytidine, Decitabine can cause DNA demethylation and could decrease expression of genes like GMAP-210. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, another HDAC inhibitor, might alter the chromatin structure affecting GMAP-210 gene expression. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 (free base) | sc-202651 | 5 mg | $151.00 | 4 | |
An inhibitor of G9a histone methyltransferase, which could change histone methylation status and gene expression patterns, including that of GMAP-210. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a DNA methyltransferase inhibitor, which may lead to gene expression changes, possibly affecting GMAP-210. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 is a selective HDAC inhibitor that could modify gene expression, potentially reducing levels of GMAP-210. | ||||||
Pargyline hydrochloride | 306-07-0 | sc-215676 sc-215676A | 500 mg 1 g | $39.00 $82.00 | 2 | |
Pargyline is a monoamine oxidase inhibitor, but it could also influence gene expression and protein modification indirectly. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
As an HDAC inhibitor, Sodium Butyrate can cause changes in acetylation of histones, potentially affecting gene expression including GMAP-210. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
It binds to DNA and selectively inhibits transcription of certain genes, which may include GMAP-210. | ||||||